CHLVPP chemotherapy with involved-field irradiation for hodgkin's disease: Favorable results with acceptable toxicity

Julie Marie Vose, Philip Jay Bierman, James R. Anderson, Dennis Weisenburger, Daniel F. Moravec, Scot Sorensen, Mark Hutchins, Monroe D. Dowling, David Howe, John Okerbloom, Robert M. Langdon, George K. Bascom, William Packard, Warren Pevnick, James Olen Armitage

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Patients with Hodgkin's disease who were previously untreated with chemotherapy received the chlorambucil, vinblastine, procarbazine, and prednisone (CHLVPP) regimen plus limited involved-field radiation therapy for treatment of Hodgkin's disease through the Nebraska Lymphoma Study Group. One hundred patients, 87 with newly diagnosed Hodgkin's disease and 13 who relapsed after receiving previous radiation therapy, were treated with this regimen between 1982 and 1989. Complete remissions (CRs) were obtained in 88 of 100 patients (88%), and there have been a total of eight relapses. The overall 3-year failure-free survival was 76%, with good-prognosis patients (ie, Karnofsky performance status ≥ 80) having a 3-year failure-free survival of 87%. Toxicity with this regimen was minimal, with neutropenic fevers reported in 13% of the patient population, moderate alopecia in 5%, and mild to moderate nausea and vomiting in 11 % of the patients. As primary-induction therapy for Hodgkin's disease, CHLVPP is an effective regimen with a high patient acceptance profile.

Original languageEnglish (US)
Pages (from-to)1421-1425
Number of pages5
JournalJournal of Clinical Oncology
Volume9
Issue number8
DOIs
StatePublished - Jan 1 1991

Fingerprint

Procarbazine
Chlorambucil
Vinblastine
Prednisone
Hodgkin Disease
Drug Therapy
Radiotherapy
Karnofsky Performance Status
Survival
Alopecia
Nausea
Vomiting
Lymphoma
Fever
Recurrence
Therapeutics

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

CHLVPP chemotherapy with involved-field irradiation for hodgkin's disease : Favorable results with acceptable toxicity. / Vose, Julie Marie; Bierman, Philip Jay; Anderson, James R.; Weisenburger, Dennis; Moravec, Daniel F.; Sorensen, Scot; Hutchins, Mark; Dowling, Monroe D.; Howe, David; Okerbloom, John; Langdon, Robert M.; Bascom, George K.; Packard, William; Pevnick, Warren; Armitage, James Olen.

In: Journal of Clinical Oncology, Vol. 9, No. 8, 01.01.1991, p. 1421-1425.

Research output: Contribution to journalArticle

Vose, JM, Bierman, PJ, Anderson, JR, Weisenburger, D, Moravec, DF, Sorensen, S, Hutchins, M, Dowling, MD, Howe, D, Okerbloom, J, Langdon, RM, Bascom, GK, Packard, W, Pevnick, W & Armitage, JO 1991, 'CHLVPP chemotherapy with involved-field irradiation for hodgkin's disease: Favorable results with acceptable toxicity', Journal of Clinical Oncology, vol. 9, no. 8, pp. 1421-1425. https://doi.org/10.1200/JCO.1991.9.8.1421
Vose, Julie Marie ; Bierman, Philip Jay ; Anderson, James R. ; Weisenburger, Dennis ; Moravec, Daniel F. ; Sorensen, Scot ; Hutchins, Mark ; Dowling, Monroe D. ; Howe, David ; Okerbloom, John ; Langdon, Robert M. ; Bascom, George K. ; Packard, William ; Pevnick, Warren ; Armitage, James Olen. / CHLVPP chemotherapy with involved-field irradiation for hodgkin's disease : Favorable results with acceptable toxicity. In: Journal of Clinical Oncology. 1991 ; Vol. 9, No. 8. pp. 1421-1425.
@article{c54249d8063b4ee8bebd2f4cd61d51e3,
title = "CHLVPP chemotherapy with involved-field irradiation for hodgkin's disease: Favorable results with acceptable toxicity",
abstract = "Patients with Hodgkin's disease who were previously untreated with chemotherapy received the chlorambucil, vinblastine, procarbazine, and prednisone (CHLVPP) regimen plus limited involved-field radiation therapy for treatment of Hodgkin's disease through the Nebraska Lymphoma Study Group. One hundred patients, 87 with newly diagnosed Hodgkin's disease and 13 who relapsed after receiving previous radiation therapy, were treated with this regimen between 1982 and 1989. Complete remissions (CRs) were obtained in 88 of 100 patients (88{\%}), and there have been a total of eight relapses. The overall 3-year failure-free survival was 76{\%}, with good-prognosis patients (ie, Karnofsky performance status ≥ 80) having a 3-year failure-free survival of 87{\%}. Toxicity with this regimen was minimal, with neutropenic fevers reported in 13{\%} of the patient population, moderate alopecia in 5{\%}, and mild to moderate nausea and vomiting in 11 {\%} of the patients. As primary-induction therapy for Hodgkin's disease, CHLVPP is an effective regimen with a high patient acceptance profile.",
author = "Vose, {Julie Marie} and Bierman, {Philip Jay} and Anderson, {James R.} and Dennis Weisenburger and Moravec, {Daniel F.} and Scot Sorensen and Mark Hutchins and Dowling, {Monroe D.} and David Howe and John Okerbloom and Langdon, {Robert M.} and Bascom, {George K.} and William Packard and Warren Pevnick and Armitage, {James Olen}",
year = "1991",
month = "1",
day = "1",
doi = "10.1200/JCO.1991.9.8.1421",
language = "English (US)",
volume = "9",
pages = "1421--1425",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "8",

}

TY - JOUR

T1 - CHLVPP chemotherapy with involved-field irradiation for hodgkin's disease

T2 - Favorable results with acceptable toxicity

AU - Vose, Julie Marie

AU - Bierman, Philip Jay

AU - Anderson, James R.

AU - Weisenburger, Dennis

AU - Moravec, Daniel F.

AU - Sorensen, Scot

AU - Hutchins, Mark

AU - Dowling, Monroe D.

AU - Howe, David

AU - Okerbloom, John

AU - Langdon, Robert M.

AU - Bascom, George K.

AU - Packard, William

AU - Pevnick, Warren

AU - Armitage, James Olen

PY - 1991/1/1

Y1 - 1991/1/1

N2 - Patients with Hodgkin's disease who were previously untreated with chemotherapy received the chlorambucil, vinblastine, procarbazine, and prednisone (CHLVPP) regimen plus limited involved-field radiation therapy for treatment of Hodgkin's disease through the Nebraska Lymphoma Study Group. One hundred patients, 87 with newly diagnosed Hodgkin's disease and 13 who relapsed after receiving previous radiation therapy, were treated with this regimen between 1982 and 1989. Complete remissions (CRs) were obtained in 88 of 100 patients (88%), and there have been a total of eight relapses. The overall 3-year failure-free survival was 76%, with good-prognosis patients (ie, Karnofsky performance status ≥ 80) having a 3-year failure-free survival of 87%. Toxicity with this regimen was minimal, with neutropenic fevers reported in 13% of the patient population, moderate alopecia in 5%, and mild to moderate nausea and vomiting in 11 % of the patients. As primary-induction therapy for Hodgkin's disease, CHLVPP is an effective regimen with a high patient acceptance profile.

AB - Patients with Hodgkin's disease who were previously untreated with chemotherapy received the chlorambucil, vinblastine, procarbazine, and prednisone (CHLVPP) regimen plus limited involved-field radiation therapy for treatment of Hodgkin's disease through the Nebraska Lymphoma Study Group. One hundred patients, 87 with newly diagnosed Hodgkin's disease and 13 who relapsed after receiving previous radiation therapy, were treated with this regimen between 1982 and 1989. Complete remissions (CRs) were obtained in 88 of 100 patients (88%), and there have been a total of eight relapses. The overall 3-year failure-free survival was 76%, with good-prognosis patients (ie, Karnofsky performance status ≥ 80) having a 3-year failure-free survival of 87%. Toxicity with this regimen was minimal, with neutropenic fevers reported in 13% of the patient population, moderate alopecia in 5%, and mild to moderate nausea and vomiting in 11 % of the patients. As primary-induction therapy for Hodgkin's disease, CHLVPP is an effective regimen with a high patient acceptance profile.

UR - http://www.scopus.com/inward/record.url?scp=0025741823&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025741823&partnerID=8YFLogxK

U2 - 10.1200/JCO.1991.9.8.1421

DO - 10.1200/JCO.1991.9.8.1421

M3 - Article

C2 - 2072145

AN - SCOPUS:0025741823

VL - 9

SP - 1421

EP - 1425

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 8

ER -